ThermoGenesis Announces Abstracts to Be Presented at Upcoming Stem Cell Therapy Conference
Read time:
ThermoGenesis Corp. has announced that its devices will be the subject of several scientific abstracts to be presented at the International Stem Cell Therapy (ISCT) 2009 Annual Meeting in San Diego, May 3-6.
The abstracts will cover the efficacy of the Company's BioArchive® System, MarrowXpress™ (MXP™) and Res-Q™ devices in the processing of stem cells from cord blood and bone marrow.
Additional abstracts will address the impact of sterilization practices on stem cell processing, and findings regarding the collection of equine stem cells. The Company will also be demonstrating its products at booth #200.
"We are delighted to have the opportunity to contribute to this leading stem cell industry conference. We believe this forum provides us the opportunity for the industry to be aware of the value of our devices in the collection and storage of stem cells from cord blood and bone marrow, as well as our ability to bring innovation to the market through devices such as the MXP and Res-Q," said Matthew Plavan, Chief Executive Officer of ThermoGenesis.
The abstracts to be presented at the ISCT include:
• Findings from a company study designed to evaluate the efficiency of stem cell recovery from bone marrow following processing with the MXP and cryopreservation with the BioArchive. This study was conducted prior to the commercial launch of the MXP in late 2008. The data demonstrated nearly one hundred percent stem cell recovery and that the MXP can be successfully used to volume reduce and harvest stem cells from human bone marrow in a functionally closed system.
• Results from a company study using the Res-Q, a point-of-care device that enables efficient collection of stem cells from bone marrow aspirate and platelet rich plasma from whole blood in less than 15 minutes. In the study, the device was used to process four bone marrow samples and six peripheral blood units. The device demonstrated the ability to efficiently separate stem cells from both sources in a consistent, uniform volume. The Res-Q is not yet commercially available; the release of this device is expected in June 2009.
• A review by the company of current practices for the sterilization of medical disposables intended for stem cell processing using ethylene oxide (EtO) from a toxicology perspective.
• Three abstracts detailing findings from studies involving the collection of stem cells from equines, including one that demonstrates the effectiveness of the Company's Res-Q for collecting stem cells from equine bone marrow aspirate and platelet rich plasma from whole blood. In addition, studies conducted in conjunction with the University of California, Davis, School of Veterinary Medicine explore the value of equine umbilical cord blood as a source of stem cells and how certain biomaterials may enhance the value of equine stem cells and the implications of these findings for human applications in the future.
"These abstracts are significant as they not only demonstrate the efficacy of our devices, but also with presentations such as our review of sterilization practices, demonstrate ThermoGenesis' goal of advancing the field of cell therapy," said John Chapman, PhD, Vice President of Scientific Affairs who directs the Company's clinical programs.
"We look forward to interacting with leading clinicians and solution providers in the stem cell sector at the upcoming ISCT and identifying new opportunities for the use of our cell processing technology," he added.
The abstracts will cover the efficacy of the Company's BioArchive® System, MarrowXpress™ (MXP™) and Res-Q™ devices in the processing of stem cells from cord blood and bone marrow.
Additional abstracts will address the impact of sterilization practices on stem cell processing, and findings regarding the collection of equine stem cells. The Company will also be demonstrating its products at booth #200.
"We are delighted to have the opportunity to contribute to this leading stem cell industry conference. We believe this forum provides us the opportunity for the industry to be aware of the value of our devices in the collection and storage of stem cells from cord blood and bone marrow, as well as our ability to bring innovation to the market through devices such as the MXP and Res-Q," said Matthew Plavan, Chief Executive Officer of ThermoGenesis.
The abstracts to be presented at the ISCT include:
• Findings from a company study designed to evaluate the efficiency of stem cell recovery from bone marrow following processing with the MXP and cryopreservation with the BioArchive. This study was conducted prior to the commercial launch of the MXP in late 2008. The data demonstrated nearly one hundred percent stem cell recovery and that the MXP can be successfully used to volume reduce and harvest stem cells from human bone marrow in a functionally closed system.
• Results from a company study using the Res-Q, a point-of-care device that enables efficient collection of stem cells from bone marrow aspirate and platelet rich plasma from whole blood in less than 15 minutes. In the study, the device was used to process four bone marrow samples and six peripheral blood units. The device demonstrated the ability to efficiently separate stem cells from both sources in a consistent, uniform volume. The Res-Q is not yet commercially available; the release of this device is expected in June 2009.
• A review by the company of current practices for the sterilization of medical disposables intended for stem cell processing using ethylene oxide (EtO) from a toxicology perspective.
• Three abstracts detailing findings from studies involving the collection of stem cells from equines, including one that demonstrates the effectiveness of the Company's Res-Q for collecting stem cells from equine bone marrow aspirate and platelet rich plasma from whole blood. In addition, studies conducted in conjunction with the University of California, Davis, School of Veterinary Medicine explore the value of equine umbilical cord blood as a source of stem cells and how certain biomaterials may enhance the value of equine stem cells and the implications of these findings for human applications in the future.
"These abstracts are significant as they not only demonstrate the efficacy of our devices, but also with presentations such as our review of sterilization practices, demonstrate ThermoGenesis' goal of advancing the field of cell therapy," said John Chapman, PhD, Vice President of Scientific Affairs who directs the Company's clinical programs.
"We look forward to interacting with leading clinicians and solution providers in the stem cell sector at the upcoming ISCT and identifying new opportunities for the use of our cell processing technology," he added.
Advertisement
